Soleno Therapeutics (NASDAQ:SLNO) Receives Neutral Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Soleno Therapeutics (NASDAQ:SLNO) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $53.00 price objective on the stock, down from their prior price objective of $100.00.

A number of other research analysts have also recently commented on the company. Piper Sandler cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Wells Fargo & Company decreased their price objective on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Cantor Fitzgerald cut Soleno Therapeutics from an “overweight” rating to a “hold” rating and decreased their price objective for the company from $123.00 to $53.00 in a report on Monday. Zacks Research cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Finally, Robert W. Baird cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. Four research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Soleno Therapeutics has a consensus rating of “Hold” and an average price target of $89.20.

Soleno Therapeutics Trading Up 0.5%

Shares of Soleno Therapeutics stock opened at $52.60 on Wednesday. The stock has a market cap of $2.72 billion, a P/E ratio of 228.71 and a beta of -2.81. The stock’s 50 day simple moving average is $38.39 and its 200-day simple moving average is $47.83. Soleno Therapeutics has a 1-year low of $29.43 and a 1-year high of $90.32. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Analysts predict that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in Soleno Therapeutics by 52.8% during the third quarter. JPMorgan Chase & Co. now owns 407,444 shares of the company’s stock worth $27,543,000 after purchasing an additional 140,779 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in Soleno Therapeutics by 25.7% during the third quarter. Avoro Capital Advisors LLC now owns 2,577,777 shares of the company’s stock worth $174,258,000 after purchasing an additional 527,777 shares in the last quarter. Schroder Investment Management Group lifted its stake in Soleno Therapeutics by 1,554.9% during the third quarter. Schroder Investment Management Group now owns 280,296 shares of the company’s stock worth $19,105,000 after purchasing an additional 263,359 shares in the last quarter. Kingdon Capital Management L.L.C. purchased a new stake in shares of Soleno Therapeutics during the third quarter worth $20,348,000. Finally, Capital World Investors increased its position in shares of Soleno Therapeutics by 34.1% during the third quarter. Capital World Investors now owns 824,514 shares of the company’s stock worth $55,737,000 after acquiring an additional 209,681 shares during the period. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine acquisition drives rally — Neurocrine agreed to acquire Soleno in a cash deal near $53/share (reported deal value ~$2.9B), adding VYKAT (DCCR) to its portfolio; that takeover/offer price is the main catalyst lifting SLNO shares this week. Zacks: Soleno Therapeutics Stock Rallies
• Neutral Sentiment: EU marketing application withdrawn ahead of takeover — Soleno voluntarily withdrew its European marketing application for the rare‑disease drug as Neurocrine sharpens focus on the U.S. market; this reduces near‑term EU optionality but appears tactical given the pending acquisition. Reuters: Soleno withdraws EU application
• Neutral Sentiment: Mixed analyst stance — HC Wainwright reiterated a “neutral” rating and cut its price target to $53 (from $100), signaling analysts are aligning targets close to the deal price; that limits upside absent a competing bidder or a higher offer. Benzinga coverage
• Negative Sentiment: Class‑action over alleged misstatements — Multiple plaintiff firms have filed/announced investigations and are soliciting lead plaintiffs for a securities‑fraud suit covering March 26–Nov 4, 2025 (alleging misstatements about the DCCR Phase 3 program); May 5, 2026 is the lead‑plaintiff deadline. This creates legal and reputational overhang that can pressure the stock and complicate the deal transition. PR Newswire: Deadline in securities fraud class action
• Negative Sentiment: Multiple downgrades trim expectations — A string of firms (Wolfe, TD Cowen, Piper Sandler, Baird, Cantor Fitzgerald, Lifesci, etc.) cut ratings/targets to “hold” or similar and trimmed price targets toward ~$53, reflecting deal‑price anchoring and reduced standalone upside; analyst caution can weigh on buyers absent a higher bid or new data. Zacks: analyst downgrade coverage

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.